Literature DB >> 9001584

Radiation induced apoptosis.

M Harms-Ringdahl1, P Nicotera, I R Radford.   

Abstract

The response to ionising radiation, in terms of level of cell killing, depends on a number of factors that may be grouped into those that are genetically controlled, radiation quality and dosage, and environmental factors. There is a range of genetically controlled cellular properties such as stage of differentiation, mutations in specific genes (such as p53 and bcl-2) and stage of transformation that will determine the ability of the target cell to enter apoptosis. The so-called normal cells, are usually more radiosensitive and the majority of the cell population will enter into an apoptotic death. However, in response to high doses of ionising radiation and complex DNA damage as produced by high-LET radiation, an increased fraction of these cells will die by necrosis. There are several examples of environmental factors with relevance for the combined action of radiation and xenobiotics on carcinogenesis and in tumour therapy. In the case of normal cells, agents such as growth factors and tumour promoters, may decrease radiosensitivity. For certain type of tumour cells, radiation sensitivity can be increased in the presence of agents such as hormones, and the cells may die an apoptotic death. Removal of heavily compromised cells is essential to prevent a potential spreading of mutated clones. However, if apoptosis is inhibited (e.g., by tumour promoter), an increased fraction of damaged cells carrying genotoxic lesions may survive. This would significantly increase the risk of proliferation of precancerous cells. As discussed above, it is probably incorrect to make predictions about relative radiosensitivity based solely on mode of death. Intrinsic characteristics deriving from the cell type of origin of a line may be more important in determining radiosensitivity. The rapidly increasing knowledge about the process of radiation induced apoptosis has opened new frontiers in radiation biology, genetic toxicology, and cancer therapy and strongly motivates further research in this field.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9001584     DOI: 10.1016/s0165-1110(96)90038-x

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  8 in total

1.  Neutron-induced apoptosis of HR8348 cells in vitro.

Authors:  L P Wang; K Liang; Y Shen; W B Yin; G Hans; Y J Zeng
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Whole-body imaging of high-dose ionizing irradiation-induced tissue injuries using 99mTc-duramycin.

Authors:  Steven E Johnson; Zhixin Li; Yu Liu; John E Moulder; Ming Zhao
Journal:  J Nucl Med       Date:  2013-06-26       Impact factor: 10.057

Review 3.  Hematopoietic stem cell injury induced by ionizing radiation.

Authors:  Lijian Shao; Yi Luo; Daohong Zhou
Journal:  Antioxid Redox Signal       Date:  2014-02-10       Impact factor: 8.401

4.  Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.

Authors:  Chang F Qu; Emma Y Song; Yong Li; Syed M A Rizvi; Chand Raja; Ross Smith; Alfred Morgenstern; C Apostolidis; Barry J Allen
Journal:  Clin Exp Metastasis       Date:  2006-02-11       Impact factor: 5.150

5.  Effects of ionizing radiation on brain tissue surrounding arteriovenous malformations: an experimental study in a rat caroticojugular fistula model.

Authors:  Melike Mut; Kamil Oge; Faruk Zorlu; Ulkü Undeğer; Sevim Erdem; Osman Ekin Ozcan
Journal:  Neurosurg Rev       Date:  2003-11-15       Impact factor: 3.042

6.  Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.

Authors:  Shuimei Luo; Long Chen; Xiuping Chen; Xianhe Xie
Journal:  Oncotarget       Date:  2015-06-30

7.  Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer.

Authors:  Heng Lin; Shuimei Luo; Lina Li; Sijing Zhou; Ruifen Shen; Haitao Yang; Yupeng Wu; Xianhe Xie
Journal:  Mol Clin Oncol       Date:  2017-02-03

8.  Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.

Authors:  Hongqing Zhuang; Zhiyong Yuan; Jun Wang; Lujun Zhao; Qingsong Pang; Ping Wang
Journal:  Drug Des Devel Ther       Date:  2013-10-08       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.